Efficacy observation of interferon, interleukin-2 and thalidomide for treatment of two acute myeloid leukemia patients with minimal residual disease-positive / 白血病·淋巴瘤

Objective To explore the effectiveness of interferon, interleukin-2 and thalidomide (IIT regimen) for treatment of acute myeloid leukemia (AML) patients with minimal residual disease (MRD)-positive. Methods Two AML patients in Henan Tumor Hospital who were still MRD-positive after consolidation therapy received IIT regimen, and the bone marrow aspirate was also detected. Results MRD of the two patients turned negative after IIT regimen. Conclusion Maintenance therapy with IIT regimen in AML patients can turn MRD-positive to be negative after consolidation therapy.